HBV特异性T淋巴细胞输注治疗慢性乙型肝炎临床研究  

Study on the Administration of Human Specific CTL for HBV to Chronic Hepatitis B

作　　者：张春兰[1] 袁小珍[1] 黄梅芳[1] 范慧敏[1] 唐小平[1] 杨湛[1] 

机构地区：[1]广东省广州市第八人民医院,广州510060

出　　处：《中国临床医学》2001年第6期589-591,共3页Chinese Journal of Clinical Medicine

基　　金：1995年广东省重点攻关项目 95 0 39

摘　　要：目的 :为探讨HBV特异性T淋巴细胞疗法的抗病毒疗效。方法 :应用此疗法治疗慢性乙型肝炎 15例 ,观察治疗后肝功能、乙肝病毒标记物 (HBVM)、细胞免疫、可溶性白细胞介素 2受体 (sIL - 2R)水平变化 ,并追踪随访 1年。结果 :经该疗法治疗后患者HBsAg、HBeAg、HBVDNA滴度均有下降 ,以随访 6个月时最明显 (P <0 .0 5 )。随访 12个月时HBeAg转阴 6例(4 0 .0 0 % ) ,HBVDNA转阴 6例 (4 0 .0 0 % )。治疗后CD8明显升高 (P <0 .0 5 ) ,完全反应者 ,sIL - 2R水平明显升高 (P <0 .0 5 )。结论 :HBV特异性T淋巴细胞输注疗法有抗病毒作用及近期疗效。Objective: To study the effect of the therapy of specific CTL for HBV on hepatitis B. Methods: 15 patients with chronic hepatitis B were administrated to the therapy of specific CTL for HBV and followed up for one year. Liver function test , HBVM, cellular immunity and sIL-2R were investigated. Results: The titers of HBsAg, HBeAg, HBVDNA in sera of patients after therapy were decreased and the titers were lowest at the follow-up for 6 months ( P <0.05). At the time of follow-up for 12 months, 6 patients were negative for HBeAg (40.00%), 6 negative for HBVDNA (40.00%). After therapy , the value of CD 8 in sera of patients was significantly high ( P <0.05). Conclusion: The therapy of specific CTL for HBV has some effect on inhibiting HBV replication and some effect for treating chronic hepatitis B in recent.

关 键 词：慢性乙型肝炎 HBV特异性T淋巴细胞 可溶性白细胞介素2受体 输注治疗 

分 类 号：R512.62[医药卫生—内科学]